Scaled-Up Production of Liposome-Encapsulated Hemoglobin.
Patent, Filed 29 Aug 86, patented 11 Oct 88,
DEPARTMENT OF THE NAVY WASHINGTON DC
Pagination or Media Count:
Objects of the present invention are to provide 1. A blood substitute or blood extender, for administration to human or animal patients 2. A substitute which is also an oxygen carrier, based upon hemoglobin, capable of circulating many hours within the circulatory system of the recipient and having adequate oxygenation characteristics, and consisting of hemoglobin-containing liposomal vesicles which are of nearly a uniform size, averaging 0.2 microns in diameter, having generally a simple lipid bilayer and which are sterilizable 3. A process for preparing a blood substitute or blood extender without chemical reaction to modify native hemoglobin, and via an aseptic process capable of yielding at least 10 mlmin of sterile product 4. A blood substitute or blood extender which has a half-life, as measured in mice, of at least 15 hours and 5. A method or producing blood substitutes or blood extenders that is a large-batch or continuous flow encapsulation system which can be easily scaled up. A method for making sterile liposome-encapsulated hemoglobin having an oxygen carrying capacity of 20 vol, a half life of 15-20 hours as measured in mice, with the liposome made from chloroform, HSPC, cholesterol, negatively charged DMPG and alpha-tocopherol is disclosed. Keywords Patents. aw
- Medicine and Medical Research